Rating Change
Roth Capital analysts downgraded LB Pharmaceuticals Inc Common Stock (NASDAQ:LBRX) from Buy to Neutral on October 05, 2026.
downgradeNASDAQ:LBRX
LB Pharmaceuticals Inc Common Stock (LBRX) Downgraded to Neutral by Roth Capital
Roth Capital analysts downgraded LB Pharmaceuticals Inc Common Stock (NASDAQ:LBRX) from Buy to Neutral on October 05, 2026.
At publication ·
What changed
LB Pharmaceuticals Inc Common Stock (NASDAQ:LBRX) · downgrade
- Firm
- Roth Capital
- Rating
- Buy to Neutral
- Price at event
- $34.62
- Market capitalization
- $508.8M
At a glance
Key takeaways
- Roth Capital downgraded LB Pharmaceuticals (LBRX) from Buy to Neutral on October 5, 2026, while the stock trades at $34.62 with a $508.8M market cap.
Market Context
LB Pharmaceuticals Inc Common Stock operates in the Healthcare sector. The stock currently trades at $34.62 with a market capitalization of $508.8M.
Analyst downgrades can weigh on a stock in the short term as institutional investors who follow Roth Capital's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for LB Pharmaceuticals Inc Common Stock
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 05, 2026 | Roth Capital | Neutral | N/A |
| Oct 02, 2026 | Needham | Buy | N/A |
| Aug 24, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 12, 2026 | BMO Capital | Outperform | N/A |
| Aug 03, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View LBRX Stock Page
Frequently Asked Questions
What does the Neutral rating mean for LBRX?
A rating of Neutral from Roth Capital reflects the analyst's outlook on LB Pharmaceuticals Inc Common Stock (NASDAQ:LBRX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the LBRX forecast page.